Cytokinetics, Incorporated (CYTK)

About Cytokinetics, Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

As of November 3, 2026, Cytokinetics, Incorporated (CYTK) stock rose to $62.98, up 1.53% (+$0.95) versus the previous close. On the day, shares have traded between $62.60 and $64.37. That puts CYTK in the lower third of its 52-week range of $58.05 to $88.31. Cytokinetics, Incorporated operates in the pharmaceutical preparations space and carries a market capitalization of roughly $8.76 billion, with about 492.8K shares changing hands.

Latest CYTK news

• Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026Yahoo Finance· Nov 2, 7:30 AM ETHCMS
• Will Alector (ALEC) Report Negative Q3 Earnings? What You Should KnowYahoo Finance· Oct 29, 9:00 AM ETALEC
• Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance· Oct 28, 9:00 AM ET
• Cytokinetics to Announce Third Quarter Results on November 4, 2026Yahoo Finance· Oct 21, 4:00 PM ET
• William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageYahoo Finance· Oct 21, 12:30 PM ET
• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance· Oct 19, 4:00 PM ET
• BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA SaysYahoo Finance· Oct 19, 11:42 AM ETBBIOMDGL
• Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Yahoo Finance· Oct 19, 8:40 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want CYTK headlines, alerts and AI research in one place? Create a free account →

• $CYTK I see a nice easy move for pre pdufa from these levels for a few days hold.

  @StMichaelTwits· Nov 3, 8:41 AM ET· Bullish

• nothing landing on the FDA clock today and the next 7 days stay quiet too imo. NRXP already landed early, approved Oct 30 ahead of its Nov 10 goal, so that date is off the board the next cluster is Nov 14, a Saturday so Friday is the practical window. $CYTK aficamten MAPLE HCM…

  @BiotechSwings· Nov 3, 8:26 AM ET

• Two company-stated FDA dates on Nov 14, 2026: $CYTK aficamten sNDA: "The FDA assigned a standard review classification to the sNDA with a PDUFA date of November 14, 2026." $SMMT ivonescimab + chemo (EGFR-mutated NSCLC): "the goal Prescription Drug User Fee Act (…

  @ORIONBiotechIntelligence· Nov 3, 1:23 AM ET

• $CYTK Q3 2026 results call: Wed Nov 4, 4:30 p.m. ET (scheduled, per company release). Chart: last close $63.31 (Oct 29). Above the 20-day EMA; below the 50-day SMA, 200-day SMA (EMA20 $63.16, SMA50 $67.78, SMA200 $70.09). RSI(14) 47. 20-day range $59.79-$66.91. Webcast: https:…

  @Merlintrader· Oct 30, 10:16 AM ET

• TRADE ALERT: $CYTK Catalyst runup Entry: $62.00 to $64.00 Stop: $60.00 Targets: $65.75, then $68.78 Score: 72 Nov 14 is 16 days out for the MAPLE HCM label supplement on MYQORZO, and the drug is already approved in obstructive HCM so this is about getting strong Phase 3 data i…

  @BiotechSwings· Oct 29, 12:28 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →